IL10 and prostate carcinoma: Nevertheless, we re-analyzed an independent group of eleven patients with metastasized, castration-resistant prostate cancer receiving one cycle of treatment with 223Ra and found exactly the same phenomenon, a negative correlation between tumor burden and antigen-specific IL-10 secretion at baseline [16].